Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The first part of the study will determine the highest dose of study drug that can be taken
without causing serious side effects in patients with lymphoma. The appropriate dose
determined from the first part of the study will be used in the second part of the study to
assess disease response in 2 different types of lymphoma patients.